Answers are grounded in this paper and cite their sources.
Randomized double-blind trial demonstrates significant eosinophil reduction with cendakimab in eosinophilic gastritis and duodenitis, suggesting interleukin-13 inhibition is a viable therapy.
INTRODUCTION: Eosinophilic gastritis (EG) and/or eosinophilic duodenitis (EoD; EG/EoD) are rare, chronic inflammatory disorders lacking approved treatments. METHODS: We report a randomized, double-blind, placebo-controlled phase 3 trial evaluating cendakimab, an anti-IL-13 monoclonal antibody, in 48 Japanese patients with EG/EoD. RESULTS: At week 16, cendakimab significantly reduced mean peak gastrointestinal eosinophil counts versus placebo (least squares mean difference −223.2 eosinophils/high-power field; P =0.003), with numerical improvements across symptom domains. Histologic effects were maintained at week 48 and a favorable safety profile was observed. DISCUSSION: These findings highlight IL-13 inhibition as a potential treatment strategy for EG/EoD.
No takes yet. Share an insight, caveat, or question.
Kinoshita et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: